Global End-Stage Renal Disease Pipeline Insight Report 2021 Featuring Aronora, Ionis Pharmaceuticals, Janssen Research & Development, & Ardelyx – ResearchAndMarkets.com | Financial Buzz

Global End-Stage Renal Disease Pipeline Insight Report 2021 Featuring Aronora, Ionis Pharmaceuticals, Janssen Research & Development, & Ardelyx – ResearchAndMarkets.com

The “End-Stage Renal Disease – Pipeline Insight, 2021” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This “End-Stage Renal Disease – Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in End-Stage Renal Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Report Highlights

  • The companies and academics are working to assess challenges and seek opportunities that could influence End-Stage Renal Disease R&D. The therapies under development are focused on novel approaches to treat/improve End-Stage Renal Disease.

End-Stage Renal Disease Emerging Drugs Chapters

This segment of the End-Stage Renal Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

End-Stage Renal Disease Emerging Drugs

  • AB002: Aronora, Inc.

Mechanism of Action: Protein C stimulants. The phase 2 of clinical trials are going on to study safety and efficacy of AB002 in end stage renal disease patients on chronic hemodialysis.

  • ISIS 416858: Ionis Pharmaceuticals

ISIS 416858 is a Factor XI inhibitor. A phase 2 clinical study evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of ISIS 416858 for participants with ESRD (end stage renal disease) receiving chronic hemodialysis as assessed by FXI activity reduction.

End-Stage Renal Disease: Therapeutic Assessment

This segment of the report provides insights about the different End-Stage Renal Disease drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in End-Stage Renal Disease

There are approx. 5+ key companies which are developing the therapies for End-Stage Renal Disease. The companies which have their End-Stage Renal Disease drug candidates in the mid to advanced stage, i.e. phase III and Phase II include, Aronora Inc., and others.

The report covers around 5+ products under different phases of clinical development like

  • Mid-stage products (Phase II and Phase I/II)
  • Early-stage products (Phase I/II and Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

Route of Administration

End-Stage Renal Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Subcutaneous
  • Intravenous
  • Oral
  • Parenteral
  • Intramuscular
  • Molecule Type

Products have been categorized under various Molecule types such as

  • Small molecules
  • Peptides
  • Polymer
  • Gene Therapy
  • Monoclonal antibodies
  • Product Type

The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

End-Stage Renal Disease: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses End-Stage Renal Disease therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging End-Stage Renal Disease drugs.

End-Stage Renal Disease Report Insights

  • End-Stage Renal Disease Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

End-Stage Renal Disease Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions Answered

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing End-Stage Renal Disease drugs?
  • How many End-Stage Renal Disease drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of End-Stage Renal Disease?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the End-Stage Renal Disease therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for End-Stage Renal Disease and their status?
  • What are the key designations that have been granted to the emerging drugs?

Key Players

  • Aronora Inc.
  • Ionis Pharmaceuticals
  • Janssen Research & Development, LLC
  • Ardelyx

Key Products

  • AZD1722
  • AB002
  • ISIS 416858
  • Rivaroxaban

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/1le6kp

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900